Volume 54, Number 8
Data from the Joint Breast Cancer Registry in Singapore were used to study patients treated with T-DXd.
Findings reveal that reduced dose intensity had no significant impact on real-world progression-free
survival or treatment-related toxicities.
Illustration by Maria De-Castro
Original Article
Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting
Human epidermal growth receptor 2 (HER2)-positive breast cancer is recognised as a particularly aggressive subtype, associated with a poorer prognosis and a higher risk...
Review Article
Integrating traditional Chinese medicine into disease management in Singapore
Traditional Chinese medicine (TCM) was introduced to the Singapore population by early Chinese immigrants from China.1 During Singapore’s colonial era, particularly between 1819 to...
Editorial
Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility
Trastuzumab deruxtecan (T-DXd), an anti-human epidermal growth receptor 2 (HER2) antibody-drug conjugate (ADC), has emerged as a transformative therapy for metastatic breast cancer (MBC),...
Original Article
Automatic brain segmentation in cognitive impairment: Validation of AI-based AQUA software in the Southeast Asian BIOCIS cohort
Dementia is a heterogeneous disorder that is accompanied by brain alterations, such as grey matter (GM) loss and cerebral small vessel disease burden, including...
Original Article
Factors associated with persistent high healthcare service utilisers in Singapore: A population health analysis
Singapore’s healthcare system comprises private and public sector providers,1 financed through a combination of government subvention and subsidies, personal medical savings and funds, health...
